doi:10.3969/j.issn.1004-583X.2022.02.015

Abstract

CLC Number:

R587.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.02.015

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I2/170

Figures/Tables 1

References 34

[1]	Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2020,16(10):556-577. doi: 10.1038/s41574-020-0392-2 pmid: 32855502
[2]	Nagahisa T, Saisho Y. Cardiorenal protection: Potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes[J]. Diabetes Ther, 2019,10(5):1733-1752. doi: 10.1007/s13300-019-00680-5 pmid: 31440988
[3]	Zinman B, Wanner C, Lachin JM, et al. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. N Engl J Med, 2015,373(22):2117-2128. doi: 10.1056/NEJMoa1504720 URL
[4]	Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019,380(4):347-357. doi: 10.1056/NEJMoa1812389 URL
[5]	Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019,380(24):2295-2306. doi: 10.1056/NEJMoa1811744 URL
[6]	Fadini GP, Solini A, Manca ML, et al. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world:A multicentre retrospective study[J]. Diabetes Obes Metab, 2019,21(2):252-260. doi: 10.1111/dom.13508 pmid: 30136354
[7]	Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care[J]. Circulation, 2019,139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177 URL
[8]	Udell JA, Yuan Z, Rush T, et al. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor:Results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)[J]. Circulation, 2018,137(14):1450-1459. doi: 10.1161/CIRCULATIONAHA.117.031227 URL
[9]	Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes,2018.A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabet, 2018,61(12):2461-2498.
[10]	Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2020,41:255-323. doi: 10.1093/eurheartj/ehz486 URL
[11]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021,37(4):311-398.
[12]	Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1,SGLT2 and GLUT2[J]. Diabetologia, 2018,61(10):2087-2097. doi: 10.1007/s00125-018-4656-5 URL
[13]	Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport[J]. Curr Opin Nephrol Hypertens, 2015,24(5):463-469. doi: 10.1097/MNH.0000000000000152 URL
[14]	Chawla G, Chaudhary KK. A complete review of empagliflozin:Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus[J]. Diabetes Meta Syndr, 2019,13(3):2001-2008.
[15]	Vijayakumar S, Vaduganathan M, Butler J. Glucose-lowering therapies and heart failure in type 2 diabetes mellitus:Mechanistic links,clinical data,and future directions[J]. Circulation, 2018,137(10):1060-1073. doi: 10.1161/CIRCULATIONAHA.117.032099 pmid: 29506996
[16]	Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes[J]. Diabetes Res Clin Pract, 2014,104(3):297-322. doi: 10.1016/j.diabres.2014.02.014 URL
[17]	Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb,randomized,placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2013,15(8):721-728. doi: 10.1111/dom.12081 pmid: 23398530
[18]	Fitchett D, Inzucchi SE, Wanner C, et al. Relationship between hypoglycaemia,cardiovascular outcomes,and empagliflozin treatment in the EMPA-REG OUTCOME^® trial[J]. Eur Heart Jl, 2020,41(2):209-217.
[19]	Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor,as add-on to metformin in type 2 diabetes with mild hyperglycaemia[J]. Diabetes Obes Metab, 2013,15(12):1154-1160. doi: 10.1111/dom.12185 pmid: 23906374
[20]	Søfteland E, Meier JJ, Vangen B, et al. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin:A 24-week randomized,double-blind,parallel-group trial[J]. Diabetes Care, 2017,40(2):201-209. doi: 10.2337/dc16-1347 pmid: 27913576
[21]	Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin:A 78-week randomized,double-blind,placebo-controlled trial[J]. Diabetes Obes Metab, 2015,17(10):936-948. doi: 10.1111/dom.12503 pmid: 26040302
[22]	Mancia G, Cannon CP, Tikkanen I, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication[J]. Hypertension, 2016,68(6):1355-1364. doi: 10.1161/HYPERTENSIONAHA.116.07703 URL
[23]	Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk:Lessons learned from the EMPA-REG OUTCOME study[J]. Diabetes care, 2016,39(5):717-725. doi: 10.2337/dc16-0041 pmid: 27208375
[24]	Sanidas EA, Papadopoulos DP, Hatziagelaki E, et al. Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension[J]. Am J Hypertens, 2020,33(3):207-213. doi: 10.1093/ajh/hpz157 pmid: 31541572
[25]	Ross S, Thamer C, Cescutti J, et al. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin:A 16-week,randomized,placebo-controlled trial[J]. Diabetes Obes Metab, 2015,17(7):699-702. doi: 10.1111/dom.12469 pmid: 25827441
[26]	Roden M, Merker L, Christiansen AV, et al. Safety,tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes:A double-blind extension of a Phase III randomized controlled trial[J]. Cardiovasc Diabetol, 2015,14:154. doi: 10.1186/s12933-015-0314-0 URL
[27]	Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level:A meta-analysis of randomized controlled trials[J]. Diabetes Obes Metab, 2018,20(2):458-462. doi: 10.1111/dom.2018.20.issue-2 URL
[28]	Ahmadieh H, Azar S. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus[J]. Diabetes Technol Ther, 2017,19(9):507-512. doi: 10.1089/dia.2017.0070 URL
[29]	Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME^® trial[J]. Eur Heart J, 2018,39(5):363-370. doi: 10.1093/eurheartj/ehx511 pmid: 29020355
[30]	Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus,established cardiovascular disease,and chronic kidney disease[J]. Circulation, 2018,137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268 URL
[31]	Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction[J]. J Am Coll Cardiol, 2021,77(3):243-255. doi: 10.1016/j.jacc.2020.11.008 pmid: 33197559
[32]	Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes[J]. N Engl J Med, 2016,375(4):323-334. doi: 10.1056/NEJMoa1515920 URL
[33]	Bae JH, Park EG, Kim S, et al. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes:A systematic review and meta-analysis of randomized controlled trials[J]. Sci Rep, 2019,9(1):1-9.
[34]	Schorling OK, Clark D, Zwiener I, et al. Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus[J]. Adv Ther, 2020,37(8):3463-3484. doi: 10.1007/s12325-020-01329-7 URL

	安慰剂(n=4 904)		恩格列净10/25 mg (n=10 177)
	例(%)	率/ 100人年	例(%)	率/ 100人年
尿路感染(BIcMQ)	691(14.1)	9.7	1 382(13.6)	9.27
生殖道感染(BIcMQ)	75(1.5)	0.95	565(5.6)	3.54
低血糖(狭义SMQ)	1 045(21.3)	16.32	2 067(20.3)	15.69
确认低血糖不良事件	987(20.1)	-	1 948(19.1)	-
基线使用胰岛素和(或) 磺脲类后确认的低血糖^a	915(30.2)	20.36	1 833(31.5)	20.88
DKA(狭义BIcMQ)	4(0.1)	0.05	6(0.1)	0.04
尿路致癌性^b(BIcMQ)	9(0.2)	0.11	23(0.2)	0.14
肝损伤(SMQ)	157(3.2)	2.02	247(2.4)	1.51
骨折(BIcMQ)	134(2.7)	1.72	233(2.3)	1.42
胰腺炎(SMQ)	11(0.2)	0.14	15(0.1)	0.09
截肢风险(ITT 人群)	46(0.9)	0.52	95(0.9)	0.52
轻微	27(0.6)	0.30	76(0.8)	0.41
严重	19(0.4)	0.21	19(0.2)	0.10
肾损害	169(3.4)	2.18	291(2.9)	1.78
急性肾损伤^c	44(0.9)	0.56	57(0.6)	0.34

	安慰剂(n=4 904)		恩格列净10/25 mg (n=10 177)
	例(%)	率/ 100人年	例(%)	率/ 100人年
尿路感染(BIcMQ)	691(14.1)	9.7	1 382(13.6)	9.27
生殖道感染(BIcMQ)	75(1.5)	0.95	565(5.6)	3.54
低血糖(狭义SMQ)	1 045(21.3)	16.32	2 067(20.3)	15.69
确认低血糖不良事件	987(20.1)	-	1 948(19.1)	-
基线使用胰岛素和(或) 磺脲类后确认的低血糖^a	915(30.2)	20.36	1 833(31.5)	20.88
DKA(狭义BIcMQ)	4(0.1)	0.05	6(0.1)	0.04
尿路致癌性^b(BIcMQ)	9(0.2)	0.11	23(0.2)	0.14
肝损伤(SMQ)	157(3.2)	2.02	247(2.4)	1.51
骨折(BIcMQ)	134(2.7)	1.72	233(2.3)	1.42
胰腺炎(SMQ)	11(0.2)	0.14	15(0.1)	0.09
截肢风险(ITT 人群)	46(0.9)	0.52	95(0.9)	0.52
轻微	27(0.6)	0.30	76(0.8)	0.41
严重	19(0.4)	0.21	19(0.2)	0.10
肾损害	169(3.4)	2.18	291(2.9)	1.78
急性肾损伤^c	44(0.9)	0.56	57(0.6)	0.34

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 34

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lv Shasha, Song Jinlan, Shi Jian. Mitochondrial mutation m.3243A> G associated with diabetes mellitus: One case report and literature review [J]. Clinical Focus, 2024, 39(2): 160-163.
[2]	Zhang Jianan, Sun Linlin, Zhan Xiaoyan, Li Bing. Correlation between serum Vitamin B₁₂ and mild cognitive impairment in elderly patients with type 2 diabetes mellitus [J]. Clinical Focus, 2024, 39(1): 34-37.
[3]	Liao Kunfeng, Yao Yisong, Yang Jinpan, Yang Xining, Li Yaru, Zhou Hongyan, Liang Piao. Status and influencing factors of fear of progression in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(12): 1095-1100.
[4]	Shi Peihua, Lin Yanlin, Bi Lifang. Study on the correlation of NLR, PLR and MLR with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2023, 38(11): 996-1001.
[5]	Yang Xin, Xu Huajiao. Bibliometric analysis of literatures reporting psychological intervention of patients with diabetes mellitus: Based on Web of Science [J]. Clinical Focus, 2023, 38(8): 731-736.
[6]	Jin Jiahui, Yang Yang, Qin Tong, He Yuxin, Su Meihua. Probiotic supplementation on improving glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(7): 581-587.
[7]	Wu Yanan, Yan Tianmei, Liang Peng, Wei Limin. High-risk identification of depressive symptoms in middle-elderly patients with diabetes [J]. Clinical Focus, 2023, 38(6): 516-520.
[8]	Yang Minxing, Sun Lu, Ye Yun, Xu Wendong, Huang Xiaolin, Zhang Haiyun, Xu Yinglei. Characteristics of cognitive function and corresponding factors in young and middle-aged patients with type 2 diabetes with obstructive sleep apnea hypopnea syndrome [J]. Clinical Focus, 2023, 38(3): 216-220.
[9]	Rao Xiaojuan, Shi Shuangwei, Sang Yanhong. Comparison of short-term efficacy of insulin degludec/insulin versus continuous subcutaneous infusion of insulin asparton diabetic patients admitted in non-endocrinology departments [J]. Clinical Focus, 2023, 38(2): 132-136.
[10]	Xie Feifei, Zhang Weijian. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(1): 20-36.
[11]	Wang Cui, Lin Hao, Wu Pingping, Zhang Yali, Ren Jian, Xu Ting, Dong Guoyu, Zai Guotian. Correlation between hyperhomocysteinemia and early renal disease in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(1): 42-45.
[12]	. [J]. Clinical Focus, 2023, 38(1): 79-83.
[13]	Wang Runqing, Wang Qian, Liao Jianxiong. A network meta-analysis of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes [J]. Clinical Focus, 2022, 37(12): 1061-1073.
[14]	Wang Wenqi, Zhang Tao. Effect of semaglutide on total myocardial ischemic burden and serum inflammatory factors in patients with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2022, 37(11): 996-1000.
[15]	. [J]. Clinical Focus, 2022, 37(10): 953-956.